The protocol: Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel

E. M. Zelenskaya, O. L. Barbarash, V. I. Ganyukov, N. A. Kochergin, K. A. Apartsin, A. V. Gorokhova, S. A. Papeshina, K. Yu Nikolaev, K. Yu Batueva, S. V. Yankovskaya, O. V. Tronin, G. I. Lifshits

    Результат исследования: Научные публикации в периодических изданияхстатьярецензирование


    Aim. To assess the association of efficacy and safety endpoints with simultaneous carriage of polymorphic variants of the gene CYP2C19: rs4244285 (*2), and rs12248560 (*17) in treatment with clopidogrel. Material and methods. In the study, 289 patients included, from large cities of Siberia, underwent coronary stenting for acute coronary syndrome. All participants were assessed for alleles CYP2C19*2, *3, *17, and clinical outcomes were followed for 30 days (thrombotic complications, bleedings). Results. It was found that simultaneous carriage of CYP2C19*2 and CYP2C19*17 alleles is associated with the risk of serious adverse events development of thrombotic origin comparing to the absence of such polymorphism carriage (p=0,016), and with general adverse events risk related to insufficiency of clopidogrel action (p=0,046). Conclusion. According to the study results, subjects with the *2/*17 carriage should be classified to a delayed clopidogrel metabolism group, as in the group definite and probable stent thrombosis were found significantly more prevalent.

    Язык оригиналаанглийский
    Страницы (с-по)113-117
    Число страниц5
    ЖурналRussian Journal of Cardiology
    Номер выпуска10
    СостояниеОпубликовано - 2017


    Подробные сведения о темах исследования «The protocol: Influence of the combination carriage CYP2C19*2 and *17 on efficacy of clopidogrel». Вместе они формируют уникальный семантический отпечаток (fingerprint).